This website is no longer actively maintained
Some material and features may be unavailable

Timeline: The story of Avandia

GlaxoSmithKline’s (GSK) controversial diabetes drug Avandia (generic name Rosiglitazone) works by helping diabetics balance their blood-sugar levels. Since its inception, it has been found to increase the risk of heart attacks and strokes — and even death. Nearly half a million people are taking the medication, which translates into approximately $900 million in annual sales. Below is a Need to Know chronology highlighting Avandia’s history leading up to a big decision by the FDA on whether to pull it from the shelves.